Genetic Aberrations in Oral Dysplasia Point to Cancer Progression

Published Online: Tuesday, September 18, 2012
Follow Pharmacy_Times:

Chromosomal changes at the allele level were recently found to influence the progression of oral dysplasia into malignant lesions, according to a new prospective study of 296 patients with mild or moderate keratotic abnormalities.

To fully understand how oral precancers can become cancerous, scientists in this study used their prior research, which showed that loss of heterozygosity (LOH) on the short arms of chromosomes 3 and 9 was associated with oral cancer development. LOH occurs when a somatic cell heterozygous for a deleterious mutant allele and a normal allele goes through a deletion or other mutational event on the normal copy, rendering the gene inactive. This gene inactivation could stop the production of tumor suppressor genes.

Investigators grouped the patients into low-, intermediate-, and high-risk groups based on the chromosomal location of the LOH. Five-year progression rates were found to be 3.1% for the low-risk group, 16.3% for the intermediate-risk group, and 63.1% for the high-risk group. This means that 2 of 3 high-risk cases are progressing, according to the study authors.



Related Articles
Citing a risk of spreading unsuspected cancer, the FDA is advising against the use of laparoscopic power morcellators in the removal of the uterus or fibroids in the majority of women.
Amgen has discontinued its studies on rilotumumab in advanced gastric cancer after an increased number of deaths were reported among patients receiving rilotumumab and chemotherapy, compared with those only undergoing chemotherapy.
Clinical practice guidelines for the diagnosis and treatment of certain types of cancer are surprisingly unstandardized.
A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.
Latest Issues
$auto_registration$